Axiom Biosciences pursues unconventional route to build biotech company
By Dr. Zubair Khalid, DVM, MS, PhD ·
Axiom Biosciences is taking a nontraditional approach to raising capital and developing new therapies, according to a recent episode of Fierce Biotech’s “The Top Line” podcast.
Founder and CEO Remo Moomiaie-Qajar spoke with Fierce Biotech’s Marissa Russo about the company’s financing strategy, its drug development approach, and upcoming clinical milestones. The discussion focused on how Axiom Biosciences is building itself differently from typical biotech startups.
The company’s model combines capital raising with therapy development in a way that departs from standard industry practice. Moomiaie-Qajar explained the rationale behind this structure and what it means for the company’s pipeline. He also outlined near-term clinical events that observers can expect from Axiom Biosciences.
The specific details of the financing mechanism, therapeutic focus, and trial timeline were not disclosed in the episode summary. The podcast is part of Fierce Biotech’s ongoing coverage of business and development strategies across the life sciences industry.
For the broader biotech sector, alternative company-building models are worth watching. Most startups rely on venture capital funding and a conventional research and development timeline. Experimental approaches to financing and drug creation can open new pathways for bringing treatments to patients, especially in areas where traditional funding is scarce or risk is high. However, unconventional structures also bring unique challenges in governance, investor alignment, and regulatory oversight.
The episode adds to a growing conversation about how biotech companies can adapt their business models to changing market conditions. Axiom Biosciences’ progress will offer one more data point on whether alternative approaches can produce sustainable drug development.
Source: original report